{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:11:09Z","timestamp":1788966669732,"version":"build-2803163510"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background and purpose:<\/jats:title>\n                    <jats:p>Cisplatin is a cornerstone of cervical cancer treatment, but chemoresistance and toxicity limit its efficacy. The NRF2-mediated antioxidant pathway contributes to cisplatin resistance. This study investigated whether insulin-like growth factor-binding protein 3 (IGFBP3) could enhance cisplatin efficacy by suppressing NRF2 signaling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental approach:<\/jats:title>\n                    <jats:p>HeLa cervical cancer cells were treated with IGFBP3, cisplatin, or their combination. Cytotoxicity and drug synergy were evaluated using the MTT assay and combination index analysis. Oxidative stress markers and antioxidant enzyme activities were assessed. NRF2 protein expression was determined by Western blotting and ELISA. Cell migration was evaluated using a scratch assay, and NRF2 target gene expression was measured by RT-qPCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings\/Results:<\/jats:title>\n                    <jats:p>IGFBP3 combined with cisplatin produced synergistic cytotoxicity (combination index &lt;1). Compared with either monotherapy, the combination significantly suppressed NRF2 expression, increased oxidative stress, reduced antioxidant enzyme activities, and inhibited cell migration. Expression of NRF2 target genes, including HO-1, CAT, SOD, and GPX, was also downregulated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and implications:<\/jats:title>\n                    <jats:p>IGFBP3 synergized with cisplatin to inhibit cervical cancer cell proliferation and migration, at least partly through suppression of the NRF2-mediated antioxidant pathway. IGFBP3 may therefore represent a promising chemosensitizing agent for overcoming cisplatin resistance and warrants further preclinical investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/rps.rps_212_25","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:20:54Z","timestamp":1788949254000},"page":"632-644","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["IGFBP3 and cisplatin synergistically suppress HeLa cell proliferation and migration through NRF2 inhibition"],"prefix":"10.4103","volume":"21","author":[{"given":"Mahboube Rahmati","family":"Kukandeh","sequence":"first","affiliation":[{"name":"Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Ataee","sequence":"additional","affiliation":[{"name":"Medical Plants Research Center, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abouzar","family":"Bagheri","sequence":"additional","affiliation":[{"name":"Immunogenetics Research Center, Department of Clinical Biochemistry and Medical Genetics, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Gharehkhani","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shokrzadeh","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran"},{"name":"Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"R1-20260909","first-page":"1","article-title":"Human papillomavirus and cervical cancer in the microbial world: exploring the vaginal microecology","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"R2-20260909","doi-asserted-by":"crossref","first-page":"298,1","DOI":"10.3390\/pathogens12020298","article-title":"HPV and cervical cancer: a review of epidemiology and screening uptake in the UK","volume":"12","author":"Choi","year":"2023","journal-title":"Pathogens"},{"issue":"5","key":"R3-20260909","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7","key":"R4-20260909","doi-asserted-by":"crossref","first-page":"e13806,1","DOI":"10.1111\/jfbc.13806","article-title":"Combination of cyanidin-3-O-glucoside and cisplatin induces oxidative stress and apoptosis in HeLa cells by reducing activity of endogenous antioxidants, increasing bax\/bcl-2 mRNA expression ratio, and downregulating Nrf2 expression","volume":"45","author":"Li","year":"2021","journal-title":"J Food Biochem"},{"issue":"30","key":"R5-20260909","doi-asserted-by":"crossref","first-page":"eadk9878,1","DOI":"10.1126\/sciadv.adk9878","article-title":"Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity","volume":"10","author":"Sung","year":"2024","journal-title":"Sci Adv"},{"issue":"20","key":"R6-20260909","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1080\/15384101.2023.2281768","article-title":"Exosome-delivered circRNA circSYT15 contributes to cisplatin resistance in cervical cancer cells through the miR-503-5p\/RSF1 axis","volume":"22","author":"Chen","year":"2023","journal-title":"Cell Cycle."},{"key":"R7-20260909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2024.1483289","article-title":"Editorial: modulation of oxidative stress and inflammation via the NRF2 signaling pathway","volume":"15","author":"Saha","year":"2024","journal-title":"Front Pharmacol"},{"issue":"12","key":"R8-20260909","doi-asserted-by":"crossref","first-page":"2377,1","DOI":"10.3390\/antiox11122377","article-title":"Nrf2 regulates oxidative stress and its role in cerebral ischemic stroke","volume":"11","author":"Wang","year":"2022","journal-title":"Antioxidants"},{"key":"R9-20260909","first-page":"102987,1","article-title":"MCL attenuates atherosclerosis by suppressing macrophage ferroptosis via targeting KEAP1\/NRF2 interaction","volume":"69","author":"Luo","year":"2024","journal-title":"Redox Biol"},{"issue":"12","key":"R10-20260909","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14737140.2024.2438951","article-title":"NRF2\/KEAP1 signaling inhibitors in gynecologic cancers","volume":"24","author":"Fantone","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"R11-20260909","doi-asserted-by":"crossref","first-page":"2025,1","DOI":"10.3390\/ijms20082025","article-title":"Pharmacological applications of Nrf2 inhibitors as potential antineoplastic drugs","volume":"20","author":"Telkoparan-Akillilar","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R12-20260909","doi-asserted-by":"crossref","first-page":"175503","DOI":"10.1016\/j.ejphar.2023.175503","article-title":"Targeting the NRF2\/KEAP1 pathway in cervical and endometrial cancers","volume":"941","author":"Tossetta","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"R13-20260909","doi-asserted-by":"crossref","first-page":"1755,1","DOI":"10.3390\/cancers11111755","article-title":"The role of Nrf2 activity in cancer development and progression","volume":"11","author":"Zimta","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"R14-20260909","doi-asserted-by":"crossref","first-page":"164","DOI":"10.18632\/aging.204466","article-title":"Doxorubicin-induced ROS- dependent HIFla activation mediates blockage of IGF1R survival signaling by IGFBP3 promotes cardiac apoptosis","volume":"15","author":"Wen","year":"2023","journal-title":"Aging (Albany, NY)"},{"issue":"1","key":"R15-20260909","doi-asserted-by":"crossref","first-page":"60,1","DOI":"10.1186\/s12935-024-03234-3","article-title":"IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion","volume":"24","author":"Zhao","year":"2024","journal-title":"Cancer Cell Int"},{"key":"R16-20260909","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bbrc.2021.07.046","article-title":"Effects of IGFBP3 knockdown on human endometrial mesenchymal stromal cells stress- induced senescence","volume":"570","author":"Ushakov","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"R17-20260909","doi-asserted-by":"crossref","first-page":"405,1","DOI":"10.3390\/cells12030405","article-title":"Phosphorylation of IGFBP-3 by casein kinase 2 blocks its interaction with hyaluronan, enabling HA- CD44 signaling, leading to increased NSCLC cell survival and cisplatin resistance","volume":"12","author":"Coleman","year":"2023","journal-title":"Cells"},{"issue":"1","key":"R18-20260909","doi-asserted-by":"crossref","first-page":"95,1","DOI":"10.1186\/s13046-021-01898-7","article-title":"Insulin-like growth factor binding protein 3 promotes radiosensitivity of oral squamous cell carcinoma cells via positive feedback on NF-\u03baB\/IL-6\/ROS signaling","volume":"40","author":"Wang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"R19-20260909","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.bbrc.2019.04.021","article-title":"Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression","volume":"514","author":"Su","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"R20-20260909","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4103\/RPS.RPS_62_25","article-title":"Synergistic cytotoxicity of recombinant IGFBP-3 and cisplatin in HPV18-positive HeLa cells via NF-\u0138B inflammatory modulation","volume":"21","author":"Arab","year":"2026","journal-title":"Res Pharm Sci"},{"issue":"13","key":"R21-20260909","doi-asserted-by":"crossref","first-page":"4777,1","DOI":"10.3390\/ijms21134777","article-title":"NRF2, a transcription factor for stress response and beyond","volume":"21","author":"He","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"R23-20260909","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/1735-5362.394819","article-title":"Clinicopathological correlation of insulin-like growth factor binding protein 3 and their death receptor in patients with gastric cancer","volume":"19","author":"Ansari","year":"2024","journal-title":"Res Pharm Sci"},{"issue":"2","key":"R24-20260909","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/RPS.RPS_247_22","article-title":"Evaluation of in vitro and in vivo anticancer activities of potassium koetjapate: a solubility-improved formulation of koetjapic acid against human colon cancer","volume":"19","author":"Jafari","year":"2024","journal-title":"Res Pharm Sci"},{"issue":"4","key":"R25-20260909","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4103\/1735-5362.235160","article-title":"In silico interaction of insulin-like growth factor binding protein 3 with insulin-like growth factor 1","volume":"13","author":"Jafari","year":"2018","journal-title":"Res Pharm Sci"},{"key":"R26-20260909","first-page":"1483,1","article-title":"Mechanisms and applications of the anti-cancer effect of pharmacological ascorbic acid in cervical cancer cells","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"R27-20260909","doi-asserted-by":"crossref","first-page":"105438","DOI":"10.1016\/j.jff.2023.105438","article-title":"Effect of ginsenoside CK combined with cisplatin on the proliferation and migration of human cervical cancer HeLa cells via Ras\/ERK\/MAPK pathway","volume":"102","author":"Li","year":"2023","journal-title":"J Funct Foods"},{"issue":"2","key":"R28-20260909","doi-asserted-by":"crossref","first-page":"90,1","DOI":"10.1038\/s41419-022-05547-5","article-title":"PDHB-AS suppresses cervical cancer progression and cisplatin resistance via inhibition on Wnt\/\u03b2- catenin pathway","volume":"14","author":"Chi","year":"2023","journal-title":"Cell Death Dis"},{"issue":"9","key":"R29-20260909","doi-asserted-by":"crossref","first-page":"830","DOI":"10.4236\/jct.2014.59091","article-title":"Activation of various downstream signaling molecules by IGFBP-3","volume":"5","author":"Shahjee","year":"2014","journal-title":"J Cancer Ther"},{"issue":"2","key":"R30-20260909","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1677\/ERC-09-0106","article-title":"Nuclear export and mitochondrial and endoplasmic reticulum localization of IGF-binding protein 3 regulate its apoptotic properties","volume":"17","author":"Paharkova-Vatchkova","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"R31-20260909","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","article-title":"NRF2 and the hallmarks of cancer","volume":"34","author":"de la Vega","year":"2018","journal-title":"Cancer cell"}],"container-title":["Research in Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/RPS.RPS_212_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:17:29Z","timestamp":1788963449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/RPS.RPS_212_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/rps.rps_212_25","relation":{},"ISSN":["1735-5362","1735-9414"],"issn-type":[{"value":"1735-5362","type":"print"},{"value":"1735-9414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2025-11-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}